Patents Assigned to Sankyo Company Limited
  • Publication number: 20250049782
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibodydrug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Application
    Filed: September 19, 2024
    Publication date: February 13, 2025
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
  • Patent number: 12220604
    Abstract: A therapeutic agent for a metastatic brain tumor comprising, as an active component, an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond and/or a method of treatment for a metastatic brain tumor, comprising administering the antibody-drug conjugate to a subject in need of the treatment for a metastatic brain tumor.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: February 11, 2025
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kiyoshi Sugihara, Chiaki Ishii
  • Publication number: 20250042947
    Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, 10 addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st X to the 12th X counting from the amino terminus.
    Type: Application
    Filed: October 15, 2024
    Publication date: February 6, 2025
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto
  • Publication number: 20250034274
    Abstract: This invention provides a novel masked antibody. The masked antibody is a molecule that binds to a target antigen, which comprises a moiety binding to a target antigen, a first peptide recognizing a target antigen-binding site comprised in such moiety, and a second peptide comprising an amino acid sequence cleaved by a protease, wherein, after the second peptide is cleaved by a protease, the molecule has higher binding intensity to the target antigen, compared with that before it is cleaved.
    Type: Application
    Filed: November 29, 2022
    Publication date: January 30, 2025
    Applicant: DAIICHI SANKYO COMPANY , LIMITED
    Inventors: Shota KUDO, Mikihiro ISHIZUKA, Reiko KAMEI, Tomoko TERAUCHI, Kazunori SAEKI
  • Publication number: 20250009725
    Abstract: The present invention provides a pharmaceutical composition in which valemetostat or a pharmaceutically acceptable salt thereof, particularly valemetostat tosylate, has excellent dissolution properties. It was found that excellent dissolution properties can be achieved by combining valemetostat or a pharmaceutically acceptable salt thereof with one or more of croscarmellose sodium and sodium starch glycolate.
    Type: Application
    Filed: November 9, 2022
    Publication date: January 9, 2025
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Naho WATANABE, Hiroshi YAMAKOSE, Masami TAKEMURA
  • Patent number: 12186310
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: March 3, 2023
    Date of Patent: January 7, 2025
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
  • Publication number: 20240400681
    Abstract: Provided are methods for producing a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert human T cell suppression function.
    Type: Application
    Filed: July 9, 2024
    Publication date: December 5, 2024
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
  • Publication number: 20240390512
    Abstract: The present disclosure relates to the field of therapeutic methods for treating a cancer using an ADC. The present disclosure also relates to the field of pharmaceutical products comprising the ADC for treating a cancer. More specifically, the ADC is composed of an anti-cadherin-6 (CDH6) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor, and the cancer may be resistant to chemotherapy.
    Type: Application
    Filed: September 14, 2022
    Publication date: November 28, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shotaro NAGASE, Chiemi SAITO, Hirokazu SUZUKI
  • Patent number: 12145987
    Abstract: Provided is a composition for cytotoxic T cell depletion, comprising an anti-LAG-3 antibody or a binding fragment thereof having the properties described in (i) to (iii) below: (i) having in vitro ADCC activity; (ii) reducing, in a low fucose form, the number of LAG-3 positive cells in vivo; and (iii) binding to activated human T cells. Also provided are methods for depleting cytotoxic T cells using the disclosed anti-LAG-3 antibody or binding fragment thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 19, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Naoki Kiyosawa, Shinnosuke Yamada
  • Publication number: 20240376147
    Abstract: Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.
    Type: Application
    Filed: February 13, 2024
    Publication date: November 14, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tatsuya YAMAGUCHI, Takashi Kouko, Shigeru Noguchi, Yohei Yamane, Fumikatsu Kondo, Takahiro Aoki, Tadahiro Takeda, Kohei Sakanishi, Hitoshi Sato, Tsuyoshi Ueda, Shinji Matuura, Kei Kurahashi, Yutaka Kitagawa, Tatsuya Nakamura
  • Patent number: 12138315
    Abstract: It is an object to provide an antibody specifically binding to CD37-positive tumor cells such as malignant B-cell lymphoma, an antibody-drug conjugate comprising the antibody, a pharmaceutical composition having therapeutic effects on a tumor using the antibody, a method for treating a tumor using the aforementioned pharmaceutical composition, a method for producing the antibody, and a method for producing the antibody-drug conjugate, and the like. The present invention provides an anti-CD37 antibody-drug conjugate in which an antibody is conjugated to a drug linker represented by the following formula (wherein A represents a connecting position to the antibody) by a thioether bond, specifically, a humanized anti-CD37 antibody having internalization ability and an antibody-drug conjugate containing the antibody.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: November 12, 2024
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tomoko Terauchi, Yuji Shinjo, Hajime Sugawara, Yusuke Shuchi, Riki Goto
  • Publication number: 20240360245
    Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.
    Type: Application
    Filed: April 30, 2024
    Publication date: October 31, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kazuki SATOH, Kazuki HIRAHARA, Ichiro WATANABE, Masato AMANO
  • Publication number: 20240360200
    Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
    Type: Application
    Filed: May 14, 2024
    Publication date: October 31, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
  • Patent number: 12129298
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to CD3 and uses thereof.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: October 29, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventor: Thomas Spreter Von Kreudenstein
  • Publication number: 20240336907
    Abstract: The present invention provides endo-?-N-acetylglucosaminidase (Endo-Si) cloning from a strain belonging to Streptococcus iniae and a mutant enzyme thereof, a gene encoding the enzyme, a recombinant plasmid, a transformant obtained by transformation of a cell by the plasmid and use thereof, and a method for producing e.g., a sugar chain remodeled antibody using the enzyme. A polypeptide having an amino acid sequence at amino acid positions 34 to 928 in SEQ ID NO: 2 or an amino acid sequence having the same amino acid sequence except containing one or mutations at more amino acid positions selected from the group consisting of amino acids at position 241 (D241), 190 (T190), 311 (Q311) and 360 (E360), said polypeptide exhibiting a sugar chain hydrolysis activity and/or transglycosylation activity.
    Type: Application
    Filed: September 1, 2021
    Publication date: October 10, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hanako NISHIZAWA, Yasunori ONO, Mitsuhiro IWAMOTO
  • Patent number: 12091395
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: September 17, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Publication number: 20240299573
    Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.
    Type: Application
    Filed: April 8, 2024
    Publication date: September 12, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
  • Patent number: 12083226
    Abstract: An object of the present invention is to provide a solid drug formulation having excellent stability. The solution according to the present invention is a solid drug formulation containing: a compound having formula (I): (i) D-mannitol; (ii) carmellose calcium; (iii) citric acid hydrate or the like; and (iv) ?-tocopherol.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: September 10, 2024
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroaki Arai, Shinji Yoshinaga, Yurika Ozaki
  • Publication number: 20240293567
    Abstract: Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives.
    Type: Application
    Filed: April 22, 2024
    Publication date: September 5, 2024
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toshifumi TSUDA, Toshiki TABUCHI, Hideaki WATANABE, Hiroyuki KOBAYASHI, Masayuki ISHIZAKI, Kyoko HARA, Teiji WADA, Masami ARAI
  • Publication number: 20240294610
    Abstract: It is intended to provide a novel peptide. The present invention provides a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits protease activity.
    Type: Application
    Filed: March 6, 2024
    Publication date: September 5, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto, Toshiyuki Sato, Takako Kimura, Atsushi Yamasaki, Tatsuya Inoue